Abstract
Mutation of Asp100 in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction.
A Jagerschmidt, N Guillaume, N Goudreau, B Maigret and B P Roques
Molecular Pharmacology November 1995, 48 (5) 783-789;
